Slides
Page 1
✓ vivoryon therapeutics H1 Financial Results and Business Update Webcast and Conference Call Vivoryon Therapeutics N.V. 06 August 2026
Page 2
2 Important notice and disclaimer This documenthas been preparedby VivoryonTherapeuticsN.V. (the “Company”or “We”) strictly only for discussionpurposes. This documentdoes not constituteor form part of any offeror invitationto sell or issue, any offer or inducementor invitationor commitmentto purchaseor subscribefor, or any solicitationof any offer to purchaseor subscribefor, any securities in the Company or any other entity. By reviewing this document, you represent that you are able to receive this document without contraventionof any legal or regulatoryrestrictionsapplicableto you and will not use this informationin relationto any investmentdecision. This documentand its contentsmay not be reproduced,redistributed,publishedor passed on, directly or indirectly,to any other person or published,in whole or in part, for any purpose. Failureto complywith these restrictionsmay constitutea violationof applicablesecuritieslaws. By acceptingand readingthis document,you will be deemedto agree not to disclose,reproduceor otherwisedistributeany information containedherein. Certain informationcontained in this document has been obtained from published and non-published sources prepared by third parties. While such informationis believed to be reliable for the purposes used herein,none of the Companyor its affiliates,directors,officers,employees,members,partners,shareholdersor agentsmake any representationor warrantywith respectto or assumeany responsibilityfor the accuracyof suchinformation,and suchinformationhas not beenindependentlyverifiedby the Company. Certain statementscontainedin this documentconstituteforward-looking statements,estimates,predictions,influencesand projectionswhich are subject to risks and uncertainties and may reflect various assumptions,which may or may not prove to be correct. These forward-looking statementsinclude informationabout possibleor assumedfuture results of the Company’sbusiness,financialcondition,results of operations, liquidity, business strategy, managementplans and objectives for future operations. In particular, the words “anticipate,”“believe,” “could,” “expect,” “should,” “plan,” “intend,”“estimate”and “potential,”or other similar expressionsare intendedto identify forward-looking statements. Forward-looking statementsappear in a number of places in this presentationand include, but are not limited to, statements regarding our intent, belief or current expectations. Forward-looking statements are based on our management’sbeliefs and assumptions and on information currently available to our management. Such statementsare subject to risks and uncertainties,and actual results may differ materiallyfrom those expressedor implied in the forward-looking statementsdue to of various risk factors and uncertaintiesincluding without limitationin relation to: the effectiveness of our main product candidate, and our ability to commercializeit if the regulatory approval is obtained; our ability to explore other potential fields of application of our product candidates and benefits of combinationtherapies between our product candidatesand other products; our ability to competeand conduct our business in the future; our ability to expend our limited resources and to obtain funding for our operationsnecessary to continue as a going concern or to complete further developmentand commercializationof our product candidates; the timing of and our ability to obtain and maintain regulatoryapproval for our product candidates; the initiation,timing, progress, results, and cost of our research and development programsand our current and future preclinicalstudiesand clinical trials, includingstatementsregardingthe timing of initiationand completionof studiesor trialsand relatedpreparatorywork, the periodduring which the resultsof the trials will becomeavailableand our researchand developmentprograms. These risks and uncertaintiesand other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, strategies or events may differ materially from those expressedor implied in such forward-looking statementsand from expectations. Moreover,we operate in an evolvingenvironment. Thus, new risk factors and uncertaintiesemerge from time to time and it is not possiblefor our managementto predict all risk factorsand uncertainties,nor can we assessthe impactof all factorson our businessor the extentto which any factor,or combinationof factors,may cause actualresultsto differ materiallyfromthosecontainedin any forward-lookingstatements. We qualifyall of our forward-lookingstatementsby thesecautionarystatements. Forward-looking statementsspeak only as of the date they are made, and we do not undertakeany obligationto update them in light of new informationor future developmentsor to release publicly any revisionsto these statementsin order to reflect later events or circumstancesor to reflect the occurrenceof unanticipatedevents or otherwise,except as requiredby applicablelaw.
Page 3
3 Agenda Frank Weber,MD Chief Executive Officer Marcus Irsfeld Chief Financial Officer Julia Neugebauer, PhD Chief Operating Officer 1. H1 2026 Overview 3. Advancing Strategic Priorities 4. Financial Results 2. Understanding Varoglutamstat’s MoA Michael Schaeffer, PhD Chief Business Officer 5. Q&A
Page 4
H1 2026 Overview Julia Neugebauer COO
Page 5
5 ◆ Currently in advanced term sheet negotiations for a potential licensing agreement for varoglutamstat in kidney disease1 ◆ Presented at key international kidney conference in Japan ◆ Further elucidated varoglutamstat MoA: newly identified roles in collagen maturation, ROS generation, endothelial function ◆ Cash runway into Q4 2026 ◆ Actively exploring partnership / funding options Growing momentum and robust body of evidence for varoglutamstat in kidney disease Advancing strategic priorities Strong clinical & scientific evidence Financials 1 Note that all ongoing negotiations and potential investments are subject to the typical risks and uncertainties associated with such processes and there can be no guarantee that any transaction or investment will materialize.
Page 6
Understanding Varoglutamstat’s MoA Michael Schaeffer CBO
Page 7
7 Understanding varoglutamstat’s unique mechanism of action Reduction of pro- inflammatory and pro-fibrotic signaling by destabilizing key molecules such as chemokines and reducing myofibroblast generation/activation Reduction of tubulointerstitial fibrosis and glomerulosclerosis by affecting maturation and stability of key ECM components like collagens Improvement of endothelial cell function via activation of HIF pathways and upregulation of VEGF - Reversal of capillary rarefaction → improved blood supply - Prevention of endothelial cell death - Vascular stabilization Varoglutamstat New
Page 8
8 Varoglutamstat in kidney disease: counteracting loss of kidney function at multiple levels advanced glycation end products (AGE), mitochondrial stress, ROS mechanical stress Inflammatory response Chemokines e.g. CCL2, CCL7, CX3CL1 DIABETES HYPERTENSION Varoglutamstat (Pro-) Collagens I and III, fibronectin Fibrotic response Loss of Function mitochondrial stress, apoptosis, podocyte effacement, glomerulosclerosis, tubulointerstitial fibrosis, endothelial impairment, kidney failure Varoglutamstat Adaptive cellular stress response Varoglutamstat Activation of HIF pathways
Page 9
Advancing Strategic Priorities Frank Weber CEO
Page 10
10 Specialist kidney investor independently assessing varoglutamstat’s potential in kidney disease for a potential investment Advanced term sheet negotiations for a licensing agreement for varoglutamstat with a pharmaceutical / biotech company Further discussions at various stages with additional strategic parties to maximize full potential of QPCTL platform in kidney diseases Progressing strategic priorities to secure development of varoglutamstat Multiple tracks ongoing to secure development of varoglutamstat in kidney disease1 1 Note that all ongoing negotiations and potential investments are subject to the typical risks and uncertainties associated with such processes and there can be no guarantee that any transaction or investment will materialize
Page 11
H1 2026 Financial Results Marcus Irsfeld CFO
Page 12
12 ◆ Cash runway maintained into Q4 2026; continue to actively explore strategic and financing options to strengthen financial position Key financial figures In €k Six months ended Jun 30, 2026 Six months ended Jun 30, 2025 Revenue 0 0 Research & Development expenses (1,659) (2,768) General & Administrative expenses (1,732) (2,755) Net loss for the period (3,388) (5,473) In €k Jun 30, 2026 Dec 31, 2025 Cash & cash equivalents 2,446 5,619 Financial assets 98 33
Page 13
Summary Frank Weber CEO
Page 14
14 Developing new therapies with the aim of preserving kidney function and preventing progression to kidney failure Significant unmet need in diabetic kidney disease (DKD) ~1.5M patients in U.S. and ~2.4M patients in EU with DKD stage 3b/4 Primary goal of new treatments is to stabilize / improve kidney function Compelling data with lead program varoglutamstat Differentiated MOA targeting pro - inflammatory & pro -fibrotic pathways First oral agent to show improvement and long -term stabilization of kidney function 1 Attractive opportunity with defined value-creation steps Substantial market creating blockbuster potential Advanced partnership negotiations ongoing 1 VIVIAD and VIVA-MIND Phase 2 studies in early Alzheimer's disease (AD) included prospectively defined measures of kidney function as safety and other exploratory endpoints
Page 15
Q&A
Page 16
Vivoryon Therapeutics N.V. Halle (Saale) Weinbergweg 22 06120 Halle (Saale), Germany Munich Franz-Josef-Delonge-Str. 5 81249 München, Germany IR@vivoryon.com www.vivoryon.com